Arcturus Therapeutics (ARCT) Projected to Post Quarterly Earnings on Tuesday

Arcturus Therapeutics (NASDAQ:ARCT) is projected to announce its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $14.3180 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $8.23 on Friday. The stock’s fifty day moving average is $7.20 and its two-hundred day moving average is $11.59. The firm has a market capitalization of $233.81 million, a P/E ratio of -3.35 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17.

Hedge Funds Weigh In On Arcturus Therapeutics

Large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. boosted its position in shares of Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets lifted its stake in Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Arcturus Therapeutics during the fourth quarter worth $64,000. Intech Investment Management LLC acquired a new stake in shares of Arcturus Therapeutics in the fourth quarter valued at $70,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of Arcturus Therapeutics by 65.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 4,737 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARCT has been the topic of several recent research reports. Piper Sandler lowered their price target on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Citigroup decreased their target price on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, January 6th. Roth Mkm began coverage on shares of Arcturus Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen cut Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.